Diastereomeric 6-desoxy-6-spiro-.alpha.-methylene-.gamma.-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted Michael acceptor ligand

Journal of Medicinal Chemistry
1984.0

Abstract

The diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone (4a and 5a) and of oxymorphone (4b and 5b) were prepared from their parent ketones. Diastereomers 4a and 4b were obtained from the 3,14-diacetate derivatives of naltrexone (6a) and oxymorphone (6b) by reaction with the Reformatsky reagent prepared from methyl alpha-(bromomethyl)acrylate. Deacetylation with methanol completed the synthesis. Diastereomers 5a and 5b were obtained from oxiranes 8a and 8b, respectively. The oxiranes were allowed to react with the sodium salt of ethyl acetoacetate, followed by methenation and deprotection to complete the synthesis of 5a and 5b, respectively. Compound 5a was the most potent agent tested in competition against [3H]naltrexone in the opioid radioreceptor assay. At a concentration of 5 nM this compound produced a 50% inhibition of binding. The majority of this inhibition (30%) was irreversible, i.e., it remained even after extensive washing of the membrane preparation in the presence and absence of Na+. Naloxone protected against this irreversible effect. The data suggest a receptor nucleophile, perhaps a sulfhydryl group, is located where it can add to the alpha, beta-unsaturated carbonyl system of 5a.

Knowledge Graph

Similar Paper

Diastereomeric 6-desoxy-6-spiro-.alpha.-methylene-.gamma.-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted Michael acceptor ligand
Journal of Medicinal Chemistry 1984.0
Electrophilic opioid ligands. Oxygen-tethered .alpha.-methylene-.gamma.-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6.beta.-naltrexol
Journal of Medicinal Chemistry 1992.0
Conjugate addition ligands of opioid antagonists. Methacrylate esters and ethers of 6.alpha.- and 6.beta.-naltrexol
Journal of Medicinal Chemistry 1990.0
Electrophilic .gamma.-lactone .kappa.-opioid receptor probes. Analogs of 2'-hydroxy-2-(tetrahydrofurfuryl)-5,9-dimethyl-6,7-benzomorphan diastereomers
Journal of Medicinal Chemistry 1991.0
Electrophilic .alpha.-methylene-.gamma.-lactone and isothiocyanate opioid ligands related to etorphine
Journal of Medicinal Chemistry 1990.0
Syntheses of 4,6′-epoxymorphinan derivatives and their pharmacologies
Bioorganic & Medicinal Chemistry 2008.0
Design, Synthesis, and Biological Evaluation of 6α- and 6β-N-Heterocyclic Substituted Naltrexamine Derivatives as μ Opioid Receptor Selective Antagonists
Journal of Medicinal Chemistry 2009.0
Selective reversible and irreversible ligands for the .kappa. opioid receptor
Journal of Medicinal Chemistry 1992.0
Importance of carbon 6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels
Journal of Medicinal Chemistry 1983.0
Synthesis and Opioid Receptor Affinity of a Series of Aralkyl Ethers of 6.alpha.- and 6.beta.-Naltrexol
Journal of Medicinal Chemistry 1994.0